Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apnea after 2-month vaccines in preterm infants
NCT03530124Phase 4Completed
- Sponsor
- Duke University
- Start
- Jul 2018
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pneumococcal 13-valent conjugate vaccine, diphtheria toxoid + tetanus toxoid + acellular pertussis, Hepatitis B vaccine, trivalent inactivated polio vaccine and haemophilus influenzae type b vaccine in pneumococcal infection, diphtheria, Tetanus and 4 more (2 arms), sponsored by Duke University. Primary endpoint: Occurrence of Apnea at 48 hours. Started Jul 2018; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccinediphtheria toxoid + tetanus toxoid + acellular pertussisHepatitis B vaccinetrivalent inactivated polio vaccinehaemophilus influenzae type b vaccine
03
Conditions
pneumococcal infectiondiphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NCT03530124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03530124.